[go: up one dir, main page]

BRPI0506774A - métodos de tratar ou inibir osteoporose ou osteopenia em um mamìfero, de tratar ou inibir cáncer de mama em um mamìfero, de inibir a recorrência do cáncer de mama em um mamìfero e de inibir cáncer de mama em uma mulher em alto risco, uso de um bazedoxifeno, produto, e, composição - Google Patents

métodos de tratar ou inibir osteoporose ou osteopenia em um mamìfero, de tratar ou inibir cáncer de mama em um mamìfero, de inibir a recorrência do cáncer de mama em um mamìfero e de inibir cáncer de mama em uma mulher em alto risco, uso de um bazedoxifeno, produto, e, composição

Info

Publication number
BRPI0506774A
BRPI0506774A BRPI0506774-0A BRPI0506774A BRPI0506774A BR PI0506774 A BRPI0506774 A BR PI0506774A BR PI0506774 A BRPI0506774 A BR PI0506774A BR PI0506774 A BRPI0506774 A BR PI0506774A
Authority
BR
Brazil
Prior art keywords
inhibiting
breast cancer
mammal
treating
osteopenia
Prior art date
Application number
BRPI0506774-0A
Other languages
English (en)
Inventor
Simon N Jenkis
Barry S Komm
Pol Boudes
Philip Frost
Matthew L Sherman
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0506774A publication Critical patent/BRPI0506774A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

MéTODOS DE TRATAR OU INIBIR OSTEOPOROSE OU OSTEOPENIA EM UM MAMìFERO, DE TRATAR OU INIBIR CáNCER DE MAMA EM UM MAMìFERO, DE INIBIR A RECORRêNCIA DO CáNCER DE MAMA EM UM MAMìFERO E DE INIBIR CãNCER DE MAMA EM UMA MULHER EM ALTO RISCO, USO DE UM BAZEDOXIFENO, PRODUTO, E, COMPOSIçãO A invenção diz respeito ao uso do bazedoxifeno (1-¢4-(2-azepan-1-il-etóxi)-benzil!-2-(4-hidróxi-fenil)-3-metil-1H-indol-5- ol) no tratamento ou inibição da osteoporose e da osteopenia relacionada à terapia do inibidor da aromatase.
BRPI0506774-0A 2004-01-13 2005-01-11 métodos de tratar ou inibir osteoporose ou osteopenia em um mamìfero, de tratar ou inibir cáncer de mama em um mamìfero, de inibir a recorrência do cáncer de mama em um mamìfero e de inibir cáncer de mama em uma mulher em alto risco, uso de um bazedoxifeno, produto, e, composição BRPI0506774A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53603504P 2004-01-13 2004-01-13
PCT/US2005/000803 WO2005070434A2 (en) 2004-01-13 2005-01-11 Treatment of aromatase inhibitor therapy-related osteoporosis

Publications (1)

Publication Number Publication Date
BRPI0506774A true BRPI0506774A (pt) 2007-05-22

Family

ID=34806981

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0506774-0A BRPI0506774A (pt) 2004-01-13 2005-01-11 métodos de tratar ou inibir osteoporose ou osteopenia em um mamìfero, de tratar ou inibir cáncer de mama em um mamìfero, de inibir a recorrência do cáncer de mama em um mamìfero e de inibir cáncer de mama em uma mulher em alto risco, uso de um bazedoxifeno, produto, e, composição

Country Status (19)

Country Link
US (1) US20050272717A1 (pt)
EP (1) EP1703910A2 (pt)
JP (1) JP2007517899A (pt)
KR (1) KR20060127875A (pt)
CN (1) CN1929835A (pt)
AR (1) AR048394A1 (pt)
AU (1) AU2005206137A1 (pt)
BR (1) BRPI0506774A (pt)
CA (1) CA2552725A1 (pt)
CR (1) CR8495A (pt)
EC (1) ECSP066699A (pt)
IL (1) IL176628A0 (pt)
NO (1) NO20063448L (pt)
PA (1) PA8621401A1 (pt)
RU (1) RU2006123939A (pt)
SG (1) SG149081A1 (pt)
TW (1) TW200526206A (pt)
UA (1) UA84046C2 (pt)
WO (1) WO2005070434A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1937251A2 (en) * 2005-04-25 2008-07-02 Pfizer Products Inc. Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor
BRPI0615341A2 (pt) * 2005-08-24 2011-05-17 Wyeth Corp composições farmacêuticas contendo acetato de bazedoxifeno, processo para preparação destas e comprimido ou cápsula contendo a referida composição
AU2012275036B2 (en) * 2005-08-24 2016-05-19 Wyeth Llc Bazedoxifene acetate formulations and manufacturing process thereof
EP1945224B1 (en) 2005-10-19 2012-05-02 Chavah Pty Ltd Reduction of side effects from aromatase inhibitors used for treating breast cancer
WO2013182169A1 (en) * 2012-06-07 2013-12-12 Zentiva, K. S. Process of preparation of an antioxidant-free polymorphically and chemically stable formulation of bazedoxifene acetate
CN103860496A (zh) * 2014-03-14 2014-06-18 王志刚 一种醋酸巴多昔芬分散片及其制备方法
US20160051565A1 (en) * 2014-08-20 2016-02-25 Professional Compounding Centers Of America (Pcca) Transdermal Pharmaceutical Compositions Including Testosterone and an Aromatase Inhibitor
AU2015336929B2 (en) 2014-10-22 2021-03-18 Havah Therapeutics Pty Ltd Methods of reducing mammographic breast density and/or breast cancer risk
CN104546794A (zh) * 2015-01-05 2015-04-29 万特制药(海南)有限公司 一种醋酸巴多昔芬胶囊及其制备方法
JP2018534291A (ja) 2015-10-22 2018-11-22 ハバフ セラピューティクス ピーティーワイ エルティーディー マンモグラフィ乳房密度及び／又は乳癌のリスクを低下させる方法
US11524014B2 (en) 2019-06-03 2022-12-13 Havah Therapeutics Pty Ltd. Pharmaceutical formulations and systems for delivery of an androgenic agent and an aromatase inhibitor with sustained multi-phasic release profiles and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW303299B (pt) * 1993-07-22 1997-04-21 Lilly Co Eli
US5998402A (en) * 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
US6479535B1 (en) * 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
US6583170B1 (en) * 1998-05-15 2003-06-24 Wyeth 2-Phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol and estrogen formulations
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
EP1192945A3 (en) * 2000-09-21 2004-03-03 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating osteoarthritis
CA2462081A1 (en) * 2000-10-11 2002-04-18 Laura Kragie Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
CN1658868A (zh) * 2002-06-13 2005-08-24 惠氏公司 巴泽昔芬治疗方案

Also Published As

Publication number Publication date
IL176628A0 (en) 2006-10-31
JP2007517899A (ja) 2007-07-05
CR8495A (es) 2007-03-06
CA2552725A1 (en) 2005-08-04
TW200526206A (en) 2005-08-16
SG149081A1 (en) 2009-01-29
US20050272717A1 (en) 2005-12-08
UA84046C2 (ru) 2008-09-10
WO2005070434A2 (en) 2005-08-04
KR20060127875A (ko) 2006-12-13
CN1929835A (zh) 2007-03-14
ECSP066699A (es) 2006-10-31
AR048394A1 (es) 2006-04-26
WO2005070434A3 (en) 2006-06-08
RU2006123939A (ru) 2008-02-20
PA8621401A1 (es) 2006-07-03
AU2005206137A1 (en) 2005-08-04
NO20063448L (no) 2006-09-29
EP1703910A2 (en) 2006-09-27

Similar Documents

Publication Publication Date Title
MX2024009727A (es) Terapias de combinacion.
BRPI0506774A (pt) métodos de tratar ou inibir osteoporose ou osteopenia em um mamìfero, de tratar ou inibir cáncer de mama em um mamìfero, de inibir a recorrência do cáncer de mama em um mamìfero e de inibir cáncer de mama em uma mulher em alto risco, uso de um bazedoxifeno, produto, e, composição
TN2010000209A1 (en) Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
NO20060398L (no) Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
DK1802625T3 (da) Disubstituerede pyrazolobenzodiazepiner der er nyttige som inhibitorer af CDK2 og angiogenese og til behandling af bryst-, tyktarms-, lunge- og prostatacancer
MA31150B1 (fr) Antagonistes spécifiques de vegf pour thérapie par adjuvant et néoadjuvant et traitement de tumeurs de premier stade
CL2008000020A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas sustituidas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y tumores malignos.
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
EA201170160A1 (ru) Новые ингибиторы пролиферации и активации переносчика сигнала и активатора транскрипции (stats)
WO2009015050A3 (en) Gene expression profile for predicting ovarian cancer patient survival
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
WO2009025806A3 (en) Use of vegfr-2 inhibitors for treating metastatic cancer
NO20084396L (no) Kombinasjonsterapi
WO2007061922A3 (en) Methods to predict and prevent resistance to taxoid compounds
FR2869540B1 (fr) Compositions pharmaceutiques contenant des derives de b-carboline, et leur utilisation pour le traitement des cancers
NO20084795L (no) Fremgangsmate for a behandle, diagnostisere eller detektere kreft
WO2006015079A3 (en) Erm family binding agents and their use in diagnosis and treatment of proliferative conditions
EP1774043A4 (en) COMPOSITIONS, KITS AND METHODS OF IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF CANCER
EP1814854A4 (en) Cationic cereals and analogues thereof, and their use for the prevention or treatment of cancer
BRPI0409690A (pt) associação terapêutica de um inibidor de cox-2 e um inibidor de aromatase
TW200616639A (en) Methods for treating a mammal before, during and after cardiac arrest
MXPA05011213A (es) Combinacion de un inhibidor de ciclooxigenasa-2 y un agente antineoplasico tipo alquilacion para tratamiento de neoplasia.
MX2009008073A (es) Inhibidores de epoxido hidrolasa solubles para el tratamiento de sindrome metabolico y trastornos relacionados.
BR0317491A (pt) Método de usar um inibidor de cox-2 e um inibidor de topoisomerase ii como uma terapia de combinação no tratamento de neoplasia

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.